External Science Review Board To "Audit" CDRH, Interview E-Stim Reps
This article was originally published in The Gray Sheet
Executive Summary
An external committee assigned to perform a review of scientific decisions and processes at the Center for Devices and Radiological Health will have the opportunity to interview industry members in the electronic stimulation device area, according to CDRH Director David Feigal.
You may also be interested in...
CDRH Science Review Spotlights Electrical Stimulation Devices
CDRH's fiscal year 2001 "science review" will focus on the agency's regulation of electrical stimulation devices as a case study.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.